worin Ar 1 einen unsubstltuierten oder substituierten aromatischen Rest bedeutet und mindestens einer der Reste R 1 und R 2 eine Alkenyl-, Cycloalkenyl- oder Arylmethylgruppe bedeutet, sind wirkungsvolle Photoinitiatoren für die Photopolymerlsation ungesättigter Verbindungen. Sie eignen sich Insbesondere zur Photohärtung pigmentierter Systeme.
摘要:
The invention provides mesotrione copper chelate form I and mesotrione copper chelate form II. A process for preparing mesotrione copper chelate form I and mesotrione copper chelate form II is also disclosed. Further, the present invention provides process for preparing mesotrione metal chelate polymorphs and agrochemical formulations comprising such polymorphs.
摘要:
The invention belongs to the field of chemical synthesis and discloses a new crystal form of tembotrione, which is a herbicide, a preparation method thereof, and an application thereof as a preparation for plant protection. The present invention obtains a previously unknown, stable, new crystal form D of tembotrione by a suitable method and overcomes the disadvantages of amorphous tembotrione. The crystal form D has a crystal structure completely different from three crystal forms A, B and C reported in WO08110621A, and thus fills a gap in national patent protection of this technology. Compared with tembotrione in other crystal forms, tembotrione in crystal form D has the advantages of a higher melting point, better chemical stability, lower dissolution rate, reduced solubility, and is thus suitable for long-term storage. The crystal structure is highly suitable for storing a tembotrione compound.
摘要:
Described are RORγ modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune and/or inflammatory disorders.